Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cidofovir in Kaposi's Sarcoma
NCT00019240Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 1996
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of cidofovir in Kaposi's sarcoma (KS), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 6 months. Started Nov 1996; status: completed.
02
Drugs
cidofovir
03
Conditions
Kaposi's sarcoma (KS)
Beyond the preview
Go deeper on NCT00019240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019240.